Author: Ravi Shankar

• Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development framework
• Builds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments

NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that its subsidiary, NorthStrive Biosciences Inc. (“NorthStrive Biosciences” or “NorthStrive”), has executed a Statement of Work (“SOW”) with Charles River Laboratories, Inc., NYSE: CRL (“Charles River” or “Charles River Laboratories”) to conduct analytical characterization supporting the development of NorthStrive Biosciences’ EL-22 and EL-32 engineered probiotic programs.

Under the SOW, Charles River will perform specialized analytical testing designed to characterize plasmid copy numbers in NorthStrive’s engineered bacterial product candidates. The work includes DNA isolation and preparation followed by gene copy-number analysis using specific nucleic-acid amplification and fluorescent-probe technology. Testing will be performed at Charles River’s U.S. Biologics Testing sites, generating quantitative data on the genetic constructs carried by each product candidate.

The program is intended to strengthen NorthStrive’s understanding and control of key product characteristics as EL-22 and EL-32 progress through development. Establishing reliable analytical methods for the genetic constructs carried by the engineered bacteria is an important component of building a reproducible manufacturing and characterization strategy for future clinical development. The data generated through this work will support product identity, manufacturing consistency, and comparability against previously manufactured material as EL-22 and EL-32 advance toward a more robust IND-enabling development framework.

Charles River Laboratories is a leading global provider of drug discovery, development and manufacturing support services to pharmaceutical and biotechnology companies worldwide.

Tara Lehner, Head of Development at NorthStrive Biosciences, added, “As engineered biologic products move forward in development, understanding what we are manufacturing becomes increasingly important. This work will give us quantitative analytical data around plasmid copy number and contribute to the broader characterization package we are building for EL-22 and EL-32. These are the kinds of foundational development activities that help turn an innovative platform into a reproducible and ultimately scalable pharmaceutical product.”

The work represents another step in NorthStrive’s broader effort to establish the analytical, manufacturing and development capabilities necessary to advance its engineered probiotic platform. The platform is being developed to address muscle health, including preserving muscle for patients on GLP-1 receptor agonists and other weight loss treatments, an area the Company believes represents a significant and growing market opportunity.

About EL-22 and EL-32

EL-22 and EL-32 are NorthStrive Biosciences’ investigational engineered probiotic product candidates being developed as part of the Company’s broader strategy to address muscle health and related conditions. The Company believes this approach may offer a differentiated method of biologic delivery with potential advantages in patient convenience, accessibility, and manufacturability across multiple disease areas.

About NorthStrive Biosciences Inc.

NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focused on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address the issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations, the ability to obtain, maintain and enforce patent protection, whether patent applications will issue or claims will be allowed, clinical and regulatory development timelines, potential indications, safety and efficacy, and market opportunity. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release include, but are not limited to, statements regarding the planned plasmid copy number characterization work, the anticipated scope, objectives, and timing of the planned analytical work, comparability against previously manufactured material, the strengthening of EL-22 and EL-32 product identity and manufacturing consistency, the advancement of EL-22 and EL-32 toward a more robust IND-enabling development framework, and the potential advantages of NorthStrive’s engineered probiotic platform.

The planned analytical work described in this press release has not yet been completed, and the Company cannot provide assurance that the planned study will be initiated or completed on the anticipated timeline, that it will generate the expected data, or that any results will support product identity, manufacturing consistency, comparability, or regulatory readiness. There can be no assurance that the Company will successfully advance EL-22 or EL-32, complete additional studies, obtain regulatory approvals, develop a product candidate, or generate revenue from this program.

These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact: IR@pmgcholdings.com

• Zcash ETP: Valour launches an exchange traded product providing price exposure to Zcash (ZEC), expanding regulated access to one of the digital asset ecosystem’s longest-standing privacy-focused networks.
• Traditional Market Access to ZEC: The ETP enables investors to gain exposure to ZEC through traditional brokerage accounts without the operational complexity of directly purchasing or storing digital assets.
• Expanding Valour’s Digital Asset Platform: The launch further expands Valour’s portfolio of more than 100 digital asset ETPs and reinforces its strategy of providing regulated access to a broad range of established and emerging digital asset protocols.

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — DeFi Technologies Inc. (the “Company” or “DeFi Technologies”) (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) (B3: DEFT31), a financial technology company bridging the gap between traditional capital markets and decentralized finance (“DeFi”), is pleased to announce that its subsidiary, Valour Inc., and Valour Digital Securities Limited (together, “Valour“), a leading issuer of exchange traded products (“ETPs“) has launched the Valour Zcash (ZEC) SEK ETP.

The VALOUR ZCASH (ZEC) SEK ETP began trading on the Spotlight Stock Market on September 29, 2026, under the ISIN CH1108681763. The product provides investors with exposure to the price performance of Zcash (ZEC) through an exchange traded investment product accessible through traditional brokerage infrastructure.

The launch represents another expansion of Valour’s digital asset ETP platform and expands regulated European market access to an asset that has played an important role in the development of privacy-preserving blockchain technology.

About Zcash

Launched in 2016, Zcash is a decentralized digital currency and payment network designed to provide users with greater control over the privacy of their financial transactions.

Zcash was the first widespread application of zero-knowledge proof technology known as zk-SNARKs. Its shielded transaction architecture allows transactions to be validated by the network while protecting sensitive transaction information from public disclosure. Zcash supports both shielded transactions, which can protect transaction details, and transparent transactions that operate similarly to transactions on traditional public blockchains.

ZEC is the native digital asset of the Zcash network and is used to transfer value and pay transaction fees across the network.

The launch comes amid increased market attention toward privacy-preserving digital assets and expanding regulated investment access to ZEC across global capital markets.

“Zcash represents one of the most important early applications of zero-knowledge cryptography in digital assets, and interest in privacy-preserving blockchain infrastructure continues to grow,” said Johan Wattenström, Chief Executive Officer of DeFi Technologies. “Launching a Zcash ETP is exactly the type of product innovation Valour was built to deliver. We are giving investors access to an established digital asset through the same regulated, familiar market infrastructure they use to access traditional securities, while continuing to expand the breadth and differentiation of our product platform.”

“Zcash gives users the ability to transact privately using zero-knowledge cryptography, and we have seen growing interest in ZEC from both professional and Nordic retail investors,” said Jacob Lindberg, Chief Revenue Officer of Valour. “The demand for a listed product tracking ZEC has been clear. Bringing Zcash to Spotlight gives investors a familiar way to gain exposure through their existing brokerage infrastructure without having to purchase, store or manage the underlying digital asset directly.”

The launch follows Valour’s continued expansion across European and international markets and builds on a portfolio of more than 100 digital asset ETPs spanning major digital assets, Layer 1 and Layer 2 networks, decentralized finance protocols, staking products and other emerging blockchain ecosystems.

The VALOUR ZCASH (ZEC) SEK ETP carries a management fee of 1.9%.

About DeFi Technologies
DeFi Technologies Inc. (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) (B3:DEFT31) is a financial technology company building for the convergence of traditional capital markets and decentralized finance (“DeFi”). As a publicly listed and vertically integrated digital asset platform, DeFi Technologies provides familiar, simple, secure, and regulated access to the digital asset economy through investment products, trading and liquidity infrastructure, research, and strategic capital deployment. Its business includes Valour, a leading issuer of regulated digital asset ETPs; Stillman Digital, an institutional-grade digital asset trading and liquidity platform; and DeFi Alpha, the Company’s internal business line focused on opportunistic trading, arbitrage, and other capital markets strategies. With deep expertise across capital markets and emerging technologies, DeFi Technologies is building the gateway between traditional finance and the future of digital assets. Follow DeFi Technologies on LinkedIn and X/Twitter, and for more details, visit https://defi.tech/  

DeFi Technologies Subsidiaries

About Valour
Valour Inc. and Valour Digital Securities Limited (together, “Valour”) issues exchange traded products (“ETPs”) that enable retail and institutional investors to access digital assets in a simple and secure way via their traditional bank account. Valour is part of the asset management business line of DeFi Technologies. For more information about Valour, to subscribe, or to receive updates, visit https://valour.com.

About Stillman Digital
Stillman Digital is a leading digital asset liquidity provider that offers limitless liquidity solutions for businesses, focusing on industry-leading trade execution, settlement, and technology. For more information, please visit https://www.stillmandigital.com

Cautionary note regarding forward-looking information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to proposed listing of Valour’s ETPs and DeFi Technologies’ BDRs on B3, the expected timing of listing and trading, future expansion plans into Brazil and other regions, and anticipated investor demand for digital asset ETPs; the regulatory environment with respect to the growth and adoption of decentralized finance; the pursuit by the Company and its subsidiaries of business opportunities; and the merits or potential returns of any such opportunities. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited the acceptance of Valour exchange traded products by exchanges; growth and development of decentralised finance and digital asset sector; rules and regulations with respect to decentralised finance and digital assets; fluctuation in digital asset prices; general business, economic, competitive, political and social uncertainties. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

THE CBOE CANADA EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

For further information, please contact:

Johan Wattenstrom
Chief Executive Officer
ir@defi.tech
(323) 537-7681

Hecht Brings More Than Three Decades of Experience Advising Private Equity Clients on Transactions, Fund Formation, Tax Planning, Compliance and After-Tax Value Creation

WASHINGTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN), a leading global expert firm for organizations facing crisis and transformation, today announced that Jeffrey Hecht has joined as a Senior Managing Director to lead the firm’s Private Equity Tax and Advisory Services.

Mr. Hecht, who is based in Miami, will lead the growth of the practice that serves private equity and multi-asset managers advising on transactions, fund formation, portfolio acquisition and divestures, tax planning and compliance. With more than three decades of experience, Mr. Hecht has served as the lead partner for some of the largest global private equity firms.

In his role at FTI Consulting, Mr. Hecht will work with sponsors and portfolio companies to build tax-efficient fund and deal structures, support acquisitions and divestitures, and manage compliance and planning throughout the investment period, helping clients protect and enhance economic performance.

“Our growing private equity tax and advisory services practice will help clients optimize investment strategies and enhance returns, as well as help navigate complex tax regulations, ensuring compliance while maximizing tax efficiency,” said Ingrid Rivera Noone, Co-Leader of the Real Estate Solutions practice at FTI Consulting. “Jeffrey brings an impressive track record to FTI Consulting where he will chart the continued growth of our services offering for private equity clients.”

Prior to joining FTI Consulting, Mr. Hecht served as Global and Americas Private Equity Tax Leader at EY. Previously Mr. Hecht founded and served as co-managing partner at Wave Energy Capital, an energy investment firm, and served as the New York Financial Services Real Estate Tax Leader at KPMG. Mr. Hecht is a Certified Public Accountant in New York and Florida and serves on the Frank G. Zarb School of Business Dean’s Advisory Board at Hofstra University and co-chairs its Department of Accounting Advisory Board.

Commenting on his appointment, Mr. Hecht said, “Private equity sponsors face mounting pressure from complex tax regimes, heightened regulatory scrutiny and investor demands for tax-efficient returns, all while managing fund formation, acquisitions and exits across multiple jurisdictions. I look forward to working with my colleagues to help sponsors and portfolio companies make practical, transaction-focused tax decisions that support compliance, improve tax efficiency and protect value throughout the investment lifecycle.”

Jahn Brodwin, Co-Leader of the Real Estate Solutions practice, added, “We are very excited to welcome Jeffrey to our team as we expand our bench of tax and strategic advisors with a particular focus on domestic and global private equity. His experience advising leading sponsors across complex transactions, fund structures and tax planning matters will be a tremendous asset to our clients and our growing practice.”

About FTI Consulting 
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenue during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.  
555 12^th Street NW  
Washington, DC 20004  
+1.202.312.9100 

Investor Contact:  
Mollie Hawkes 
+1.617.747.1791 
mollie.hawkes@fticonsulting.com 

Media Contact:  
Nina Dietrich 
+1.203.533.7134 
nina@ninadietrich.com

WINNIPEG, Manitoba, Sept. 29, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI or the Company) a leading manufacturer of buses and motorcoaches and a provider of comprehensive aftermarket parts and service solutions, today announced that intends to release its third quarter 2026 (Q3 2026) financial results on Thursday, November 5, 2026, after markets close, with a conference call and webcast to discuss the results on Friday, November 6, 2026 at 8:30 a.m. Central Time (CT).

For attendees who wish to join by webcast, registration is not required; the event can be accessed at https://edge.media-server.com/mmc/p/kxv5vx2g. NFI encourages attendees to join via webcast, as a results presentation will be presented, and users can also submit questions to management through the platform. The results presentation will be available at www.nfigroup.com.

Attendees who wish to join by phone must visit the following link and pre-register: https://register-conf.media-server.com/register/. An email will be sent to the user’s registered email address, which will provide the call-in details. Due to the possibility of emails being held up in spam filters, we highly recommend that attendees wishing to join via phone register ahead of time to ensure receipt of their access details.

A replay of the call will be accessible from about 12:00 p.m. ET on November 6, 2026, until 11:59 p.m. ET on November 6, 2027, at https://edge.media-server.com/mmc/p/kxv5vx2g.Other materials will also be available on NFI’s website at www.nfigroup.com.

About NFI

NFI is a leading global bus and motorcoach manufacturer and a provider of aftermarket parts and service solutions. With more than 9,000 team members across ten countries and operations spanning over 40 facilities, NFI delivers a comprehensive portfolio of bus and coach platforms.

Through its brands New Flyer^® (heavy-duty transit buses), MCI^® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), ARBOC^® (low-floor cutaway and medium-duty buses), and NFI Parts™, NFI supports a diverse and extensive portfolio, serving public transit, commuter, and coach markets. In total, NFI supports an installed base of more than 100,000 buses and coaches worldwide. NFI offers a broad range of propulsion systems, including zero-emission electric (referring to propulsion systems that do not utilize internal combustion engines, such as trolley, battery, and fuel cell), natural gas, electric hybrid, and advanced diesel technologies, providing agencies with multiple fleet technology options. NFI’s common shares trade on the Toronto Stock Exchange (TSX: NFI) and its convertible unsecured debentures trade under the symbol NFI.DB. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, nfi.parts, www.alexander-dennis.com, arbocsv.com, and carfaircomposites.com.

For investor inquiries, please contact: 
Stephen King 
P: 204.792.1300 
Stephen.King@nfigroup.com 

MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce that Mr. Jean-François Larivière has been appointed Vice President Exploration. 

Jean-François Larivière holds a B.Sc. with Honours in Earth Science, with a concentration in Economic Geology, as well as a Ph.D. in Mineral Resources from the Université du Québec à Montréal. With nearly 25 years of experience in mineral exploration, he is also an active member of the Ordre des géologues du Québec and has served on CONSOREM’s scientific management committee since 2013.

With his metallogenist background, he has worked at Midland as a project geologist and a specialist in 3D modelling, GIS data processing and information technology for 15 years. He has worked on the Company’s projects in the James Bay and Abitibi regions, in the Grenville and the Labrador Trough, which has given him the opportunity to work in a variety of geological settings. Since 2023, he has been Midland’s Chief Geologist.

Gino Roger, President and CEO of Midland, stated: “We’re very pleased to appoint Jean-François Larivière to the position of Vice President Exploration. During his many years with Midland, Jean-François has progressively risen through the ranks of our exploration team, before taking up this leadership role today. This path has allowed him to acquire in-depth knowledge of our projects, our working methods and our strategic priorities, all while developing a solid understanding of Midland’s culture, rooted in scientific diligence, collaboration, innovation and value creation through exploration. His diverse experience, technical expertise and intimate knowledge of our organization make him a natural choice to lead our exploration activities and accompany Midland through the next stages of its development.”

About Midland

Midland targets the mineral potential of Quebec to make the discovery of new deposits of gold and critical metals. Midland is proud to count on reputable partners such as Rio Tinto Exploration Canada Inc., BHP Canada Inc., Centerra Gold Inc., Barrick Mining Corporation, Agnico Eagle Mines Limited, Wallbridge Mining Company Ltd, Fresnillo plc, Electric Elements Mining Corp., SOQUEM Inc., Nunavik Mineral Exploration Fund, and Abcourt Mines Inc. Midland prefers to work in partnership and intends to quickly conclude additional agreements in regard to newly acquired properties. Management is currently reviewing other opportunities and projects to build up Midland’s portfolio and generate shareholder value.

For further information, please consult Midland’s website or contact:

Gino Roger, President and Chief Executive Officer
Tel.: 450 420-5977
Fax: 450 420-5978
Email: info@midlandexploration.com
Website: https://www.midlandexploration.com/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements include statements relating to management expectations regarding the conclusion of additional agreements in regard to newly acquired properties, and other estimates and statements that describe Midland’s future plans, objectives or goals, including words to the effect that Midland or management expects a stated condition or result to occur. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, changes in general economic conditions and conditions in the financial markets, changes in demand and prices for minerals, failure to obtain the requisite permits and approvals from government bodies and third parties, regulatory and governmental policy changes (laws and policies) and those risks set out in Midland’s public documents, including in each management discussion and analysis, filed on SEDAR+ at www.sedarplus.com. Although Midland believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, Midland disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3

PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that a Type C meeting with the U.S. Food and Drug Administration (FDA) Division of Neurology has been scheduled for October 20, 2026. The objective of this meeting is to align with the FDA on the analytical and statistical details pertaining to the proposed primary endpoint for the planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB) who experience psychosis symptoms.  

“Hallucinations are a core feature of DLB and often occur early in the disease, sometimes before cognitive changes are observed,” explained Anthony O. Caggiano, MD, PhD, CMO of Cognition. “Importantly, researchers have found that psychosis symptoms, such as hallucinations and delusions, typically worsen as DLB progresses. In previous meetings, FDA agreed that psychosis could be an approvable outcome and could represent a marker for DLB disease progression. We look forward to discussing this in more detail with our Agency colleagues in October and aligning on an approvable endpoint to deploy in our planned Phase 3 study.”

Previous meeting minutes received in June 2026 provided alignment on key aspects of a pivotal trial design, including the measurement of psychosis as a primary outcome. Cognition currently expects the Phase 3 study will enroll people with DLB who experience psychosis symptoms of hallucinations and delusions. Participants are expected to be eligible whether they are on stable background medication or are untreated. Following screening, participants will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine months.

“We look forward to meeting with the agency to finalize details of our registrational trial of zervimesine in DLB,” said Lisa Ricciardi, Cognition’s president and CEO. “Our ultimate goal is to provide patients and their families with a disease-modifying treatment option that slows the progression of DLB, and by so doing, delays the onset or worsening of symptoms.”

About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.

About DLB
Dementia with Lewy bodies (DLB) is a progressive, fatal neurodegenerative disease characterized by neuropsychiatric, cognitive and motor deficits. There are no approved drugs to slow the decline of DLB or treat the symptoms associated with the disease. Up to 80% of people living with DLB experience psychosis, which manifests as debilitating hallucinations and delusions. Hallucinations are a core feature and are among the diagnostic criteria for DLB. Psychosis symptoms are frequently cited as the most challenging for patients and their care partners to manage. The off-label use of traditional antipsychotics is often avoided due to the risk of severe and potentially life-threatening adverse reactions, underscoring a critical unmet need. In a Phase 2 trial, zervimesine slowed progression of hallucinations and delusions by 89% compared to placebo, as measured by the neuropsychiatric inventory (NPI). In studies to date, zervimesine has been generally well tolerated.

About Zervimesine (CT1812)
The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Zervimesine (CT1812) is currently being studied in the Phase 2 START Study (NCT05531656) in patients with MCI and early Alzheimer’s disease. Phase 2 clinical studies have concluded in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease, and geographic atrophy secondary to dry AMD. Based in part on the strong efficacy signals observed in the Phase 2 SHIMMER study in DLB (NCT05225415), the company plans to advance zervimesine into a registrational trial for people with DLB who experience psychosis. Zervimesine has been generally well tolerated in clinical studies to date.

The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information:    Cognition Therapeutics, Inc.     info@cogrx.com

Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa Kirin International (“KKI”), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) (“Kyowa Kirin”), a Japan-based global specialty pharmaceutical company, for mogamulizumab (sold as POTELIGEO® in the United States and Europe) across certain Latin American countries. Under the terms of this agreement Knight will be responsible for obtaining regulatory approval and commercializing mogamulizumab in Brazil, Mexico, Colombia and Argentina.

Mogamulizumab is a humanized monoclonal antibody (mAb) targeting chemokine receptor 4 (CCR4), a receptor expressed on malignant T cells. POTELIGEO® is approved in the United States and Europe for treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), after at least one prior systemic therapy, the two most common subtypes of cutaneous T-cell lymphoma (CTCL).^1,2,3

CTCL is a rare form of non-Hodgkin lymphoma that can affect the skin, blood, lymph nodes and internal organs.^4,5 CTCL often presents with persistent, inflamed skin lesions that can resemble benign dermatologic conditions, leading to delayed diagnosis and treatment. Patients frequently endure painful, itchy, and disfiguring skin symptoms that fluctuate unpredictably, contributing to physical discomfort, emotional distress, and can lead to a reduced life expectancy.⁶ Epidemiological data for CTCL in Latin America is limited, but is believed to be in line with the United States where the reported annual incidences of MF and SS are 5.42 per million and 0.21 per million, respectively.⁷ Together MF and SS represent approximately 65% of all cases of CTCL.⁵

“We are thrilled to add Kyowa Kirin, a Japan-based global specialty pharmaceutical company, as a new Knight partner. POTELIGEO® represents an innovative advancement in the treatment of rare cancers, specifically mycosis fungoides and Sézary syndrome. Its addition to our hemato-oncology portfolio addresses a significant unmet medical need and will provide patients across our key Latin American markets with access to a much-needed new therapeutic option,” said Samira Sakhia, President and CEO of Knight Therapeutics Inc.

Céline Rhême, Cluster General Manager, Emerging Growth Markets, Kyowa Kirin International, commented: “CTCL is more common in this region than many realise, and further work is needed to identify unmet needs and therefore drive improvements in patient outcomes.⁸ We have an opportunity, and a responsibility, to change that. Through our proud partnership with Knight Therapeutics, we can help to increase patient access in Latin America, as part of our ongoing and relentless commitment to bring life-changing value and make people smile.”

About Mogamulizumab

Mogamulizumab is a first-in-class humanized mAb directed against CCR4, a protein expressed on cancerous cells seen in both MF and SS. ^9,10,11 Once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.¹²

The approval of POTELIGEO® (mogamulizumab) is supported by the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) study, which is the largest randomized trial in MF and SS and the first to compare systemic therapies using progression-free survival (PFS) as a primary endpoint. MAVORIC was a Phase 3 open-label, multi-center, randomized study of mogamulizumab versus vorinostat in patients with MF and SS who have failed at least one prior systemic treatment. The study randomized a total of 372 patients to mogamulizumab or vorinostat. The results showed that mogamulizumab demonstrated significantly superior PFS at a median of 7.7 months [95% CI: 5.7, 10.3] compared to 3.1 months with vorinostat [95% CI: 2.9, 4.1], [hazard ratio 0.53: 95% CI: 0.41, 0.69; p<0.001]. The confirmed overall response rate for mogamulizumab and vorinostat was 28% and 5%, respectively (risk ratio [RR] 23.1, 95% CI 12.8–33.1; p<0.001).¹³ The most common side effects associated with mogamulizumab vs vorinostat included rash (36% vs 22%), infusion related reactions (33% vs <1%), upper respiratory tract infections (22% vs 16%), musculoskeletal pain (22% vs 17%), fever (18% vs 6%), and mucositis (14% vs 6%), respectively.¹⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. Kyowa Kirin, Inc. Poteligeo (mogamulizumab-kpkc) injection, for intravenous use [prescribing information]. Bedminster, NJ; 2018. Accessed November 11, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761051s000lbl.pdf
2. European Medicines Agency. Poteligeo: EPAR – Product information. Accessed November 11, 2025. https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf
3. Martinez XU, Di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol. 2019;32(3):239-252. doi:10.1016/j.beha.2019.06.004
4. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714. doi:10.1182/blood-2018-11-
5. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722. doi:10.1182/blood-2007-03-
6. Haun PL, Scarisbrick JJ. Fast Facts: Cutaneous T-cell Lymphoma. Karger Medical and Scientific Publishers; 2019. Accessed November 11, 2025. https://books.google.ca/books?id=bdRwEQAAQBAJ
7. Cai ZR, Chen ML, Weinstock MA, Kim YH, Novoa RA, Linos E. Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis. JAMA Oncol. 2022;8(11):1690-1692. doi:10.1001/jamaoncol.2022.
8. Dobos G, Pohrt A, Ram-Wolff C, Lebbé C, Bouaziz JD, Battistella M, Bagot M, de Masson A. Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers (Basel). 2020 Oct 11;12(10):2921. doi: 10.3390/cancers12102921. PMID: 33050643; PMCID: PMC7600606.
9. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405-1410. doi:10.1046/j.1523-1747.2002.19610.
10. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99(5):1505-1511. doi:10.1182/blood.v99.5.
11. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625-3634.
12. Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171-174. doi:10.1177/
13. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204. doi:10.1016/S1470-2045(18)30379-6
14. Kyowa Kirin, Inc. POTELIGEO (mogamulizumab for injection) [product monograph]. Bedminster, NJ: Kyowa Kirin, Inc.; June 20, 2022. Accessed November 12, 2025. https://pdf.hres.ca/dpd_pm/00066376.PDF

CONTACT INFORMATION FOR KNIGHT:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T: 514.484.4483
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

This press release was published by a CLEAR® Verified individual.

• Drilling confirms strong continuity of gold mineralisation within the Road Cut Artisanal Shear, while results from northern sections RCZ000 and RCZ-200 identify additional areas for follow-up drilling 
• KDD0191 returned 19.0 m at 1.94 g/t Au, including 9.0 m at 3.29 g/t Au, confirming continuity of mineralisation within the Artisanal Shear
• Drilling on sections RCZ000 and RCZ-200 provides further evidence that the Road Cut gold system continues north into relatively lightly drilled areas
• More than 53,430 m of drilling completed across 260 holes at Kossou, with additional high-grade results returned from the Kadie Zone

QUEBEC CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) — Kobo Resources Inc. (“Kobo” or the “Company”) (TSX.V: KRI) (FWB: Q1Z) is pleased to report diamond drill results from fourteen (14) additional holes completed at its 100%-owned Kossou Gold Project (“Kossou”) in Côte d’Ivoire. Six holes completed at the Road Cut Zone continued to extend and define gold mineralisation across multiple structures, including the Artisanal Shear, Main Road Cut Shear and Contact Zone Fault, with drilling providing further evidence that the mineralised system continues to the north. Eight additional holes tested shear and quartz-vein structures at the Kadie Zone, returning several high-grade gold intercepts.

Diamond Drill Results – Highlights:

Road Cut Zone:

• KDD0191
  • 19.0 metres (“m”) at 1.94 g/t Au from 67.0 m, incl. 14.2 m at 2.44 g/t Au and 9.0 m at 3.29 g/t Au
  • 4.0 m at 2.05 g/t Au from 134.0 m, incl. 1.0 m at 7.17 g/t Au
  • 2.0 m at 2.91 g/t Au from 156.0 m

• KDD0188
  • 7.0 m at 1.28 g/t Au from 245.0 m

• KDD0182
  • 6.0 m at 1.17 g/t Au from 36.0 m

Kadie Zone:

• KDD0192
  • 9.0 m at 2.44 g/t Au from 62.0 m, incl. 2.0 m at 9.78 g/t Au

• KDD0185
  • 2.0 m at 9.26 g/t Au from 213.0 m

Edward Gosselin, CEO and Director of Kobo, commented: “KDD0191 is an important result for our understanding of the core Road Cut system, returning a strong 19.0 m interval while confirming continuity of gold mineralisation within the Artisanal Shear. The hole also intersected additional mineralisation proximal to the Contact Zone Fault, further strengthening our understanding of how these structures contribute to the broader Road Cut gold system.”

He continued: “Separately, drilling farther north on sections RCZ000 and RCZ-200 is providing additional evidence that the Road Cut gold system continues beyond the areas we have drilled more extensively to date. These northern areas remain relatively lightly drilled and give our exploration team clear targets for follow-up as we continue testing the scale of the system.”

Road Cut Zone

KDD0191 Confirms Strong Continuity at the Artisanal Shear at the Road Cut Zone

Drill hole KDD0191 was completed on section RCZ500 (Figure 2) to test the up-dip extension of gold mineralisation associated with the Contact Zone Fault identified in KDD0170, which returned 8.0 m at 2.65 g/t Au from 355.0 m (see press release dated August 6, 2026). KDD0191 returned two intervals proximal to the Contact Zone Fault: 4.0 m at 2.05 g/t Au from 134.0 m, including 1.0 m at 7.17 g/t Au, and 2.0 m at 2.91 g/t Au from 156.0 m. These results confirm the presence of mineralisation associated with shearing and quartz veining along the structure.

KDD0191 was also designed to test continuity of the Artisanal Shear between KDD0012, which returned 11.0 m at 1.71 g/t Au (see press release dated July 11, 2024), and KDD0091, which returned 15.55 m at 2.30 g/t Au, including 8.30 m at 3.43 g/t Au, as previously reported on July 10, 2025. KDD0191 returned 19.0 m at 1.94 g/t Au from 67.0 m, including 14.20 m at 2.44 g/t Au and 9.0 m at 3.29 g/t Au, demonstrating strong continuity of gold mineralisation within the Artisanal Shear on this section. Further drilling is planned across the Main Road Cut Shear, Artisanal Shear and Contact Zone Fault, all of which remain open at depth.

Figure 1: Road Cut Zone Simplified Geology Map with Diamond Drill Hole Collars

Figure 2: Road Cut Zone Simplified Section – RCZ500

Contact Zone Fault Mineralisation Extended Farther North

Drill hole KDD0188 was completed on section RCZ-200 to test for potential mineralisation along the Contact Zone Fault farther north, based on soil geochemistry and surface mapping (Figure 3). Previous drilling in KDD0153 did not successfully intersect the interpreted fault position. Based on updated geological information, KDD0188 was collared within the volcanic package and returned three separate zones of mineralisation, highlighted by 7.0 m at 1.28 g/t Au from 245.0 m directly associated with the Contact Zone Fault.

Two additional lower-grade intervals were intersected in the hanging wall of the Contact Zone Fault, returning 4.85 m at 0.45 g/t Au from 218.0 m and 5.0 m at 0.40 g/t Au from 228.0 m. These results confirm the presence of the mineralised system at depth on this section. Further drilling is planned to test the continuity of mineralisation along the structure in this area and up-dip and down-dip of the current results.

Figure 3: Road Cut Zone Simplified Section – RCZ200

Drilling Confirms Road Cut Shear System Continues North

Two holes were completed on section RCZ000 to test the extension of the shear systems and gold mineralisation north of the main drilling completed to date at the Road Cut Zone (Figure 1). KDD0182 returned the strongest intercept of 6.0 m at 1.17 g/t Au from 36.0 m, interpreted to be associated with the structures parallel to the Road Cut Main shear system. Additional mineralised intervals included 3.0 m at 1.06 g/t Au from 156.0 m and 3.0 m at 1.22 g/t Au from 175.0 m appear to be related to the Road Cut Main shear system.

KDD0186 was completed below KDD0182 and intersected several narrow, weak-to-moderate grade zones, including 2.0 m at 2.17 g/t Au from 164.0 m, 3.0 m at 1.03 g/t Au from 186.0 m and 1.0 m at 1.47 g/t Au from 292.0 m associated with the Contact Zone Fault. These holes provide further evidence that the shear system continues north. The approximately 200 m gap between sections RCZ-200 and RCZ000 remains a target for future drilling.

Kadie Zone

Kadie Drilling Returns Additional High-Grade Gold Intercepts

Eight drill holes were completed at the Kadie Zone to test multiple shear and quartz-vein structures. Significant results include 9.0 m at 2.44 g/t Au from 62.0 m, including 2.0 m at 9.78 g/t Au, in KDD0192 on section KZ275; 2.0 m at 9.26 g/t Au from 213.0 m in KDD0185 on section KZ250; and 2.20 m at 3.91 g/t Au from 62.0 m in KDD0189 on section KZ400.

Most of these intercepts are associated with high-grade quartz-carbonate veins hosted within weakly foliated to unfoliated volcanic rocks. Additional work is required to further define the distribution and continuity of these shear and vein structures. Kobo has completed approximately 4,400 m across 25 drill holes at the Kadie Zone to date.

Figure 4: Kadie Zone Simplified Geology Map with Diamond Drill Hole Collars

Table 1: Summary of Significant Diamond Drill Hole Results

BHID	East	North	Elev.	Az.	Dip	Length		From (m)	To (m)	Int. (m)	Au g/t		Target
KDD0180	228610.55	775626.18	291.64	70	-50		131.3	79	82	3	0.57		Kadie
KDD0181	228518.77	775539.47	304.94	70	-50		273.3	NSR					Kadie
KDD0182	228204.17	776702.14	252.71	70	-50		245.4	36	42	6	1.17		RCZ
								56	59	3	0.61		RCZ
								156	159	3	1.06		RCZ
								168	170	2	0.67		RCZ
								175	178	3	1.22		RCZ
								207	213	6	0.67		RCZ
KDD0183	228601.13	775729.16	303.85	70	-50		140.3	NSR					Kadie
KDD0184	228315.79	776689.99	247.68	70	-50		155.4	33	34	1	1.03	*	RCZ
KDD0185	228528.78	775493.81	313.71	70	-50		284.3	152	153	1	1.26	*	Kadie
								200	201	1	2.26	*	Kadie
								213	215	2	9.26		Kadie
								220	221	1	1.80	*	Kadie
KDD0186	228157.18	776685.04	253.60	70	-50		311.4	103	104	1	1.68	*	RCZ
								107	109	2	0.98		RCZ
								122	123	1	1.19	*	RCZ
								164	166	2	2.17		RCZ
								173	177	4	0.58		RCZ
								186	189	3	1.03		RCZ
								204	208	4	0.38		RCZ
								292	293	1	1.47	*	RCZ
KDD0187	228610.82	775466.45	305.62	70	-50		212.3	39	41	2	0.64		Kadie
								67	68	1	1.22	*	Kadie
								126	127	1	1.01	*	Kadie
								150	152	2	1.03		Kadie
								197	200	3	1.42		Kadie
KDD0188	228043	776855	254.64	70	-50		335.4	69	72	3	1.87		RCZ
								97	98	1	1.02	*	RCZ
								218	222.85	4.85	0.45		RCZ
								228	233	5	0.40		RCZ
								245	252	7	1.28		RCZ
								271	273	2	0.64		RCZ
KDD0189	228684.17	775386.55	323.38	70	-50		221.3	10	12	2	0.56		Kadie
								62	64.2	2.2	3.91		Kadie
								71	72	1	3.49	*	Kadie
								179	180	1	3.28	*	Kadie
KDD0190	228711.20	775343.14	331.64	70	-50		215.3	100	105	5	1.99		Kadie
								100	101	1	8.34	*	Kadie
								135	136	1	2.81	*	Kadie
KDD0191	228534.21	776288.83	218.46	70	-60		179.4	67	86	19	1.94		RCZ
								69	83.2	14.2	2.44		RCZ
								69	78	9	3.29		RCZ
								134	138	4	2.05		RCZ
								137	138	1	7.17	*	RCZ
								156	158	2	2.91		RCZ
KDD0192	228356.80	775400.50	348.48	70	-50		263.3	7	9	2	0.58		Kadie
								41	49	8	0.46		Kadie
								55	57	2	2.44		Kadie
								62	71	9	2.44		Kadie
								62	64	2	9.78		Kadie
								206	208	2	1.23		Kadie
KDD0193	228251.83	776400.53	290.26	70	-50		383.4	132	136	4	0.71		RCZ
								173	177	4	0.76		RCZ
								286.9	288.9	2	1.38		RCZ
								348	350.2	2.2	0.66		RCZ
Notes: Cut-off grade of 0.30 g/t Au over a minimum interval of 2.0 m. Intervals are reported with no more than 3.0 m of internal dilution grading less than 0.30 g/t Au, except where indicated with an asterisk (*).

An accurate dip and strike and controls of mineralisation are unconfirmed and mineralised zones are reported as downhole lengths. Drill holes are planned to intersect mineralised zones perpendicular to interpreted targets. All intercepts reported are downhole distances, true widths are unknown.

Sampling, QA/QC, and Analytical Procedures

Drill core was logged and sampled by Kobo personnel at site. Drill cores were sawn in half, with one half remaining in the core box and the other half secured into new plastic sample bags with sample number tickets. Core samples are drilled using HQ core barrels to below the level of oxidation and then reduced to NQ core barrels for the remainder of the bore hole. Samples are transported to the SGS Côte d’Ivoire facility in Yamoussoukro by Kobo personnel where the entire sample was prepared for analysis (prep code PRP86/PRP94). Sample splits of 50 grams were then analysed for gold using 50g Fire Assay as per SGS Geochem Method FAA505. QA/QC procedures for the drill program include insertion of a certificated standards every 20 samples, a blank every 20 samples and a duplicate sample every 20 samples. All QAQC control samples returned values within acceptable limits.

Review of Technical Information

The scientific and technical information in this press release has been reviewed and approved by Paul Sarjeant, P.Geo., who is a Qualified Person as defined in National Instrument 43-101. Mr. Sarjeant is the President and Chief Operating Officer and Director of Kobo.

About Kobo Resources Inc.

Kobo Resources is a growth-focused gold exploration company with a compelling gold discovery in Côte d’Ivoire, one of West Africa’s most prolific gold districts, hosting several multi-million-ounce gold mines. The Company’s 100%-owned Kossou Gold Project is located approximately 20 km northwest of the capital city of Yamoussoukro and is directly adjacent to one of the region’s largest gold mines with established processing facilities.

With over 47,500 metres of diamond drilling, 5,887 metres of reverse circulation (RC) drilling, and 7,200+ metres of trenching completed since 2023, Kobo has made significant progress in defining the scale and prospectivity of its Kossou’s Gold Project. Exploration has focused on multiple high-priority targets within a 9+ km strike length of highly prospective gold-in-soil geochemical anomalies, with drilling confirming extensive mineralisation at the Jagger, Road Cut, and Kadie Zones. The latest phase of drilling has further refined structural controls on gold mineralisation, setting the stage for the next phase of systematic exploration and resource development.

Beyond Kossou, the Company is advancing exploration at its Kotobi Permit and is actively expanding its land position in Côte d’Ivoire with prospective ground, aligning with its strategic vision for long-term growth in-country. Kobo remains committed to identifying and developing new opportunities to enhance its exploration portfolio within highly prospective gold regions of West Africa. Kobo offers investors the exciting combination of high-quality gold prospects led by an experienced leadership team with in-country experience.

Kobo’s common shares trade on the TSX Venture Exchange under the symbol “KRI” and on the Frankfurt Stock Exchange under the symbol “Q1Z”. For more information, please visit www.koboresources.com.

For further information, please contact:

Edward Gosselin
Chief Executive Officer and Director
1-418-609-3587
ir@kobores.com

X: @KoboResources | LinkedIn: Kobo Resources Inc.

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Statement on Forward-looking Information:

This press release may contain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements, including statements related to the exploration program of the Company. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable as at the date of this press release, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inherent risks involved in the exploration and development of mineral properties; unanticipated costs and expenses; the delay or failure to receive board, shareholder or regulatory approvals; and other risk factors listed from time to time in documents filed by the Company with Canadian securities regulators on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, Kobo assumes no obligation or liability to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/656354d2-4c8d-43b1-aa3f-72bc61cef38e

https://www.globenewswire.com/NewsRoom/AttachmentNg/cfaab198-2080-4411-b411-4dc6d0de89e9

https://www.globenewswire.com/NewsRoom/AttachmentNg/77220253-abaa-4841-907e-38238831fb43

https://www.globenewswire.com/NewsRoom/AttachmentNg/5cfccaeb-142d-4d89-9a72-154bd5ec6947

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment

Median interval between end of initial treatment course and first retreatment infusion was 16.6 months

No new safety signals reported; safety profile consistent with previously reported data

Topline data from Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis expected in 1Q27

FREDERICK, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced additional positive retreatment data of its lead investigational asset, Descartes-08, in patients with generalized myasthenia gravis (MG), being presented today during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting being held in Orlando, Florida.

Descartes-08 is Cartesian’s autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T) in clinical development for MG and myositis. Dr. James F. Howard Jr., M.D., a distinguished neurologist at the University of North Carolina School of Medicine and investigator in the Phase 2b trial, will present the case series of five retreated patients who experienced clinically meaningful improvements in MG severity scores following a recurrence of MG symptoms at least 12 months after the initial course of Descartes-08 treatment.

“There remains a significant unmet need for patients suffering from MG today where current treatment options require patients to utilize chronic immunosuppressants to manage the disease,” said James F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine. “Descartes-08 is designed to target BCMA+ immune cells in MG to potentially provide patients with sustained symptom improvement reflected in clinically significant MG-ADL reductions with the added ability to be re-dosed if symptoms recur. For patients who have already cycled through multiple therapies, the option to retreat a CAR-T cell therapy, in an outpatient setting and without lymphodepleting chemotherapy, represents an exciting potential advancement in the field of MG.”

12-Month Retreatment Results

The data presented today at AANEM analyzed the efficacy, safety, and durability of Descartes-08 retreatment in five patients with MG who previously received a full treatment course in the Phase 2 portion of the trial and experienced recurrence of symptoms (Myasthenia Gravis Activities of Daily Living [MG-ADL] ≥6) following 12-month follow-up. Similar to the initial course of treatment, retreatment consisted of six once-weekly Descartes-08 infusions. Clinical outcomes were assessed by mean change in Myasthenia Gravis Composite (MGC) and MG-ADL scores from baseline through Month 12. Safety and tolerability were also assessed across treatment courses.​ Patients had a mean disease duration of 13 years with extensive treatment histories.

Efficacy

• Patients retreated (n=5) at a median of 16.6 months following completion of initial treatment course experienced greater improvement in MG symptoms compared to initial course of treatment; mean decrease in MG-ADL scores were sustained through 12 months following retreatment
  • Retreated patients observed an average MG-ADL reduction of 6.6 (±4.2) points from baseline at Month 12.
  • Retreated patients observed an average MGC reduction of 15 (±6.2) points from baseline at Month 12.
  • All retreated patients experienced a clinically meaningful reduction across MGC (≥3-point reduction) and MG-ADL scores (≥2-point reduction), and four patients maintained the clinically meaningful MG-ADL reduction through Month 12 following retreatment.

Safety

• Consistent safety data observed to date supports potential retreatment of Descartes-08 following recurrence of MG symptoms, as clinical benefit was observed with no new safety concerns
  • Descartes-08 was observed to be generally well-tolerated through Month 12 following retreatment, and adverse events were transient and mild. No serious adverse events were reported during retreatment. Notably, there were no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, or hypogammaglobulinemia.

“Descartes-08’s clinical data generated to date has demonstrated the potential for meaningful clinical responses that persist through 12 months following the completion of an initial course of treatment, with the ability to be re-dosed if needed. Unlike currently approved therapies that generally require cyclical dosing to maintain effect, Descartes-08 is being developed with the goal of providing sustained clinical benefit following a finite course of treatment.,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “We believe the combination of sustained symptom improvement, the ability to retreat if symptoms return, and the quality-of-life benefits of outpatient administration without lymphodepleting chemotherapy sets Descartes-08 apart and has the potential to meaningfully change the way MG is treated. These data strengthen our conviction in Descartes-08 as we approach topline results from our Phase 3 AURORA trial, expected in the first quarter of 2027.”

Descartes-08 was previously granted Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG. Cartesian received written agreement from the FDA under the Special Protocol Assessment (SPA) process indicating the overall design of the planned Phase 3 AURORA trial of Descartes-08 is acceptable to support a future biologics license application (BLA) in MG, subject to the ultimate outcome of the trial. Cartesian remains on track to readout topline data from its Phase 3 AURORA trial of Descartes-08 in MG in the first quarter of 2027, with a BLA filing expected in mid-2027.

About Descartes-08

Descartes-08, Cartesian’s lead cell therapy candidate, is an investigational, autologous CAR-T product targeting BCMA in clinical development for generalized MG and myositis, specifically dermatomyositis and antisynthetase syndrome. In contrast to conventional DNA-based CAR T-cell therapies, Cartesian’s CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG, and Rare Pediatric Disease Designation for the treatment of juvenile dermatomyositis.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Forward Looking Statements

Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, the ability of the Company’s product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, or any of the Company’s other product candidates to treat MG, juvenile MG, myositis, juvenile dermatomyositis, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, including the ongoing Phase 3 AURORA trial of Descartes-08 in MG, the ongoing Phase 2 TRITON trial of Descartes-08 in myositis, and the ongoing Phase 1/2 HELIOS pediatric trial of Descartes-08 in autoimmune diseases, including juvenile dermatomyositis, the anticipated timing or the outcome of the FDA’s review of the Company’s regulatory filings, including the number of trials that may be necessary in order to obtain marketing approval, the potential for in-vivo delivery of the Company’s product candidates, the Company’s ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the ability of the Company to enter into and maintain potential collaborations or partnerships, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company’s clinical trials and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company’s technology, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, political uncertainty, the Company’s reliance on third parties to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company’s common stock, risks related to geopolitical conflicts, pandemics, and macroeconomic impacts, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com

Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company“), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the “Board“).

Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.

“We are pleased to welcome Melanie to Optimi’s Board,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “Her extensive financial leadership experience across technology-driven and emerging growth companies, together with her public company board experience, will add valuable perspective as Optimi continues to execute on its strategic priorities and advance its position in the regulated psychedelic pharmaceutical market.”

Ms. Pump also currently serves on the Board of Directors of Mobio Technologies Inc. (TSXV: MBO) and previously served as a director of BTCS Inc. Her background combines senior financial leadership with public company governance experience across a range of technology-focused and growth-oriented businesses.

“I’m pleased to join Optimi’s Board at an important stage in the Company’s development,” said Melanie Pump. “Optimi has built a strong foundation in regulated psychedelic drug manufacturing and is advancing meaningful opportunities for growth. I look forward to working with Dane, the Board and the broader leadership team, and to contributing my experience in finance, governance and emerging growth companies as Optimi continues to execute on its strategic priorities.”

The Company also announces that Leah Hodges has resigned as Corporate Secretary of the Company. Dane Stevens, the Company’s Chief Executive Officer has been appointed to fill the role. The Company thanks Mrs. Hodges for her service.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Future results may differ materially from those expressed or implied in any forward-looking statement. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. In this news release, forward-looking statements and forward-looking information relate to, among other things, information regarding: the Company’s execution of its strategic priorities, position in the regulated psychedelic pharmaceutical market, opportunities for growth, and the contribution of Ms. Pump’s experience going forward. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. These risk factors include, among other things, market acceptance of the Company’s products, as well as those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.com and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.